The objective of this study is to evaluate the efficacy and safety of NASAFYTOL® on COVID-19
positive hospitalized patients as a supportive treatment to standard-of-care in improving
clinical parameters safely during hospital admission (maximum 14 days).
The study is a standard-of-care comparative, open, parallel two-arms and randomized trial in
50 adult patients positive to COVID-19 infection and hospitalized. It will be monocentric but
may be extended to several investigation sites (multicentric) depending on the evolution of
the epidemic within the hospitals.